Cyana Therapeutics is a precision immuno-oncology company developing drugs to treat solid tumors. Our lead compound (CY-3132) is a small molecule inhibitor of an enzyme called ENPP1, which is upregulated on the surface of many tumor cells. ENPP1 activity allows tumor cells to evade the immune system, and tumors expressing high levels of ENPP1 are often resistant to current cancer treatments. By blocking ENPP1 activity, CY-3132 restores cancer cell immune signaling, activating the body's ability to recognize and eliminate cancer cells.